H.C. Wainwright Starts Inhibikase Therapeutics Inc (IKT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Price: $1.66 +2.47%
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 24 | New: 16
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 24 | New: 16
Join SI Premium – FREE
H.C. Wainwright analyst Ed White initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Buy rating.
For an analyst ratings summary and ratings history on Inhibikase Therapeutics Inc click here. For more ratings news on Inhibikase Therapeutics Inc click here.
Shares of Inhibikase Therapeutics Inc closed at $0.58 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts Anthropic (ANT), Defers Offering Rating
- Morgan Stanley Starts Fervo Energy (FRVO) at Overweight
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
